Characteristics of patients and results
| Patient no. . | Age (y)/sex/status . | Karyotype . | PB, % of blasts/% of HER2+ population (RI) . | BM, % of blasts/% of HER2+ population (RI) . | Total no. administered (infusions of trastuzumab) . | Responses . | % of blasts at best response, no. of infusions received at best response . |
|---|---|---|---|---|---|---|---|
| 1 | 73/male/first untreated relapse | −7 | 23%/100% (6.1) | 92%/100% (11) | 18 | PRCR | 92% vs 12% (BM) |
| 100% HER2+ (RI = 3); 12 infusions received | |||||||
| 2 | 35/male/beyond first relapse | Normal 1% | 28%/100% (25) | 2 | Failure/progression | ||
| 3 | 62/male/beyond first relapse | Ph+ | 50% (100%)/(26) | 61%/100% (26) | 4 | Failure/progression | |
| 4 | 35/male/refractory | Normal 0% | 96%/100% (4.7) | 20 | Blast clearance in BM | 96% vs 57% (BM) | |
| 100% HER2+ (RI = 7.5); 8 infusions received | |||||||
| 5 | 60/female/refractory | Normal 0% | 25%/100% (9) | 13 | PR | 25% vs 11% (BM) | |
| 100% HER2+ (RI = 6); 4 infusions received | |||||||
| 6 | 63/male//beyond first relapse | Normal 82%/86% (18) | 93%/87% (10) | 2 | Failure/progression | ||
| 7 | 24/male/beyond first relapse | Complex 84%/100% (28) | 23%/100% (16) | 3 | Failure/progression | ||
| 8 | 70/female/beyond first relapse | Complex 48%/94% (40) | 58%/91% (30) | 5 | Failure/progression | ||
| 9 | 54/female/beyond first relapse | Normal 49%/86% (12.3) | 69%/83% (7.8) | 5 | Failure/progression | ||
| 10 | 62/female/beyond first relapse | Normal 45%/99% (12) | 76%/99% (28) | 3 | Blast clearance in PB | 20% vs 0% (PB) | |
| Failure in BM | 3 infusions received | ||||||
| 11 | 62/female/beyond first relapse | Ph+ | 76%/99% (20.5) | Not done | 4 | Failure/progression | |
| 12 | 25/male/beyond first relapse | Ph+ | 0% | 22%/100% (6) | 2 | Failure/progression | |
| 13 | 66/female/beyond first relapse | Complex 91%/34% (10) | 91%/31% (13) | 3 | Failure/progression | ||
| 14 | 78/female/beyond first relapse | Normal 1% | 61%/100% (15) | 2 | Failure/progression | ||
| 15 | 80/male/first untreated relapse | Unknown 0% | 80%/65% (10) | 1 | Cardiac toxicity |
| Patient no. . | Age (y)/sex/status . | Karyotype . | PB, % of blasts/% of HER2+ population (RI) . | BM, % of blasts/% of HER2+ population (RI) . | Total no. administered (infusions of trastuzumab) . | Responses . | % of blasts at best response, no. of infusions received at best response . |
|---|---|---|---|---|---|---|---|
| 1 | 73/male/first untreated relapse | −7 | 23%/100% (6.1) | 92%/100% (11) | 18 | PRCR | 92% vs 12% (BM) |
| 100% HER2+ (RI = 3); 12 infusions received | |||||||
| 2 | 35/male/beyond first relapse | Normal 1% | 28%/100% (25) | 2 | Failure/progression | ||
| 3 | 62/male/beyond first relapse | Ph+ | 50% (100%)/(26) | 61%/100% (26) | 4 | Failure/progression | |
| 4 | 35/male/refractory | Normal 0% | 96%/100% (4.7) | 20 | Blast clearance in BM | 96% vs 57% (BM) | |
| 100% HER2+ (RI = 7.5); 8 infusions received | |||||||
| 5 | 60/female/refractory | Normal 0% | 25%/100% (9) | 13 | PR | 25% vs 11% (BM) | |
| 100% HER2+ (RI = 6); 4 infusions received | |||||||
| 6 | 63/male//beyond first relapse | Normal 82%/86% (18) | 93%/87% (10) | 2 | Failure/progression | ||
| 7 | 24/male/beyond first relapse | Complex 84%/100% (28) | 23%/100% (16) | 3 | Failure/progression | ||
| 8 | 70/female/beyond first relapse | Complex 48%/94% (40) | 58%/91% (30) | 5 | Failure/progression | ||
| 9 | 54/female/beyond first relapse | Normal 49%/86% (12.3) | 69%/83% (7.8) | 5 | Failure/progression | ||
| 10 | 62/female/beyond first relapse | Normal 45%/99% (12) | 76%/99% (28) | 3 | Blast clearance in PB | 20% vs 0% (PB) | |
| Failure in BM | 3 infusions received | ||||||
| 11 | 62/female/beyond first relapse | Ph+ | 76%/99% (20.5) | Not done | 4 | Failure/progression | |
| 12 | 25/male/beyond first relapse | Ph+ | 0% | 22%/100% (6) | 2 | Failure/progression | |
| 13 | 66/female/beyond first relapse | Complex 91%/34% (10) | 91%/31% (13) | 3 | Failure/progression | ||
| 14 | 78/female/beyond first relapse | Normal 1% | 61%/100% (15) | 2 | Failure/progression | ||
| 15 | 80/male/first untreated relapse | Unknown 0% | 80%/65% (10) | 1 | Cardiac toxicity |
RI indicates ratio intensity; PRCR: partial remission cytolytic response; and PR, partial response.